Table 5 Patients achieving a satisfactory symptom state according to one or more, two or more, or three PASS criteriaa
Lumiracoxib 100 mg od (n = 811) | Lumiracoxib 100 mg od with initial dose (n = 805) | Celecoxib 200 mg od (n = 813) | Placebo (n = 806) | |
|---|---|---|---|---|
Patients considering their current state as satisfactory at week 2 according to: | ||||
One or more PASS criteria, n (%) | 396 (48.8) | 393 (48.8) | 367 (45.1) | 241 (29.9) |
Two or more PASS criteria, n (%) | 229 (28.2) | 259 (32.2) | 226 (27.8) | 128 (15.9) |
Three PASS criteria, n (%) | 128 (15.8) | 144 (17.9) | 142 (17.5) | 62 (7.7) |
Patients considering their current state as satisfactory at week 13 according to: | ||||
One or more PASS criteria, n (%) | 464 (57.2) | 478 (59.4) | 443 (54.5) | 367 (45.5) |
Two or more PASS criteria, n (%) | 340 (41.9) | 343 (42.6) | 325 (40.0) | 256 (31.8) |
Three PASS criteria, n (%) | 231 (28.5) | 230 (28.6) | 211 (26.0) | 156 (19.4) |